Walleye Capital LLC Has $68,000 Holdings in Personalis, Inc. (NASDAQ:PSNL)

Walleye Capital LLC lessened its holdings in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 92.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,848 shares of the company's stock after selling 154,940 shares during the period. Walleye Capital LLC's holdings in Personalis were worth $68,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp increased its holdings in Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company's stock worth $942,000 after purchasing an additional 44,900 shares in the last quarter. Jane Street Group LLC lifted its stake in Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company's stock valued at $884,000 after acquiring an additional 99,671 shares in the last quarter. Barclays PLC boosted its position in Personalis by 45.4% during the 3rd quarter. Barclays PLC now owns 65,468 shares of the company's stock worth $352,000 after acquiring an additional 20,444 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Personalis by 20.0% during the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company's stock worth $2,683,000 after acquiring an additional 83,068 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Personalis in the fourth quarter valued at approximately $63,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Stock Performance

Personalis stock traded up $0.37 during midday trading on Friday, reaching $4.23. 360,525 shares of the company's stock were exchanged, compared to its average volume of 975,457. The stock's 50-day simple moving average is $3.62 and its 200 day simple moving average is $4.47. The firm has a market cap of $373.54 million, a price-to-earnings ratio of -2.50 and a beta of 1.89. Personalis, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. Research analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Analysts Set New Price Targets

PSNL has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Personalis in a research note on Friday, February 28th. Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 target price on the stock. Lake Street Capital raised their price target on Personalis from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Personalis has a consensus rating of "Buy" and a consensus target price of $7.80.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.